GLENMARK

said its US subsidiary will launch Ropivacaine Hydrochloride Injection USP in the US market. The product is bioequivalent to Fresenius Kabi's Naropin injection, used for numbing body areas before surgery or childbirth and relieving pain. Glenmark plans to start distribution in November 2025, targeting a market valued at around $20.9 million.